GeoVax Labs (GOVX) Enterprise Value (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Enterprise Value of -$3.1 million for Q2 2026, down 1.6% year-over-year from -$3.2 million in Q2 2025, and down 1.87% quarter-over-quarter from -$3.1 million in Q4 2025.
GeoVax Labs (GOVX) Enterprise Value (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Enterprise Value for 17 consecutive years, with -$3.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 1.6% year-over-year to -$3.1 million; the TTM figure through Jun 2026 stood at -$3.1 million (down 1.6% YoY), while the FY2025 annual figure was -$3.1 million, up 43.97% from the prior year.
- Enterprise Value retreated to -$3.1 million in Q2 2026 per GOVX's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$768859.0 in Q1 2024 and bottomed at -$34.7 million in Q3 2022.
- Historically, Enterprise Value has averaged -$12.3 million across 5 years, with a median of -$7.4 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 96.78% — and 2025, when it sank 867.51%.
- GeoVax Labs' Enterprise Value stood at -$27.6 million in 2022, then jumped by 76.63% to -$6.5 million in 2023, then gained by 14.66% to -$5.5 million in 2024, then surged by 43.97% to -$3.1 million in 2025, then declined by 1.87% to -$3.1 million in 2026.
- Business Quant data shows GOVX's Enterprise Value at -$3.1 million in Q2 2026, -$3.1 million in Q4 2025, and -$5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | GeoVax Labs | 2.89 Mn | -257,298.12 | - | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.14 Mn |
| Dec 31, 2025 | -3.09 Mn |
| Sep 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Mar 31, 2025 | -7.44 Mn |
| Dec 31, 2024 | -5.51 Mn |
| Sep 30, 2024 | -8.59 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -768,859.00 |
| Dec 31, 2023 | -6.45 Mn |
| Sep 30, 2023 | -12.69 Mn |
| Jun 30, 2023 | -17.79 Mn |
| Mar 31, 2023 | -23.85 Mn |
| Dec 31, 2022 | -27.61 Mn |
| Sep 30, 2022 | -34.68 Mn |
| Jun 30, 2022 | -30.90 Mn |
| Mar 31, 2022 | -16.26 Mn |
| Dec 31, 2021 | -11.42 Mn |
| Sep 30, 2021 | -18.11 Mn |
| Jun 30, 2021 | -19.54 Mn |